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Available online 17 July 2019Background:With the introduction of glucagon-like peptide-2 (GLP-2) in the treatment of short bowel syndrome
(SBS), there is emerging evidence that GLP-2may play a role in the restoration of the disturbed homeostatic feed-
back in the gut-liver axis and may ameliorate SBS-associated liver damage.
We have previously presented that daily subcutaneous injectionswith 1 and 10mg of glepaglutide improved in-
testinal function in patients with SBS. As exploratory endpoints, we here assessed the effect of glepaglutide on
liver function.
Methods: Liver tests, transient elastography (TE) with controlled attenuation parameter (CAP), indocyanine
green (ICG) kinetics, soluble CD163 (sCD163), soluble mannose receptor (sMR), and lipopolysaccharide binding
protein (LBP)were assessed in 18 patientswith SBS in a randomised, cross-over, dose-findingphase 2 trial before
and after three weeks of treatment with glepaglutide. This trial is completed and registered at ClinicalTrials.gov:
NCT02690025.
Findings: Between Feb 2016 and Jan 2017, 22 patients with SBS were screened. Of these, 18 patients were
randomised and treatedwith glepaglutide; 16 patients completed the trial. Treatment with glepaglutide was as-
sociated with increase in TE and ICG-elimination. In the 10 mg dose group, glepaglutide increased sCD163 by
0·44 mg/mL (P = 0·0498), and alkaline phosphatase (ALP) decreased in the 1 mg dose group by 33 U/L (P =
0·032). CAP, sMR, LBP, liver transaminases, and INR were not affected.
Interpretation: Glepaglutide may improve hepatic excretory function, but at the same time activate resident liver
macrophages and increase liver stiffness. The excretory and the stiffness findings may to some extent relate to
increased splanchnic blood flow which would not influence the marker of macrophage activation. Thus,
glepaglutide exerted diverse effects on liver status that call for attention in future studies.
Funding: Zealand Pharma.
This is an open access article under the CC BY-NC-ND license. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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C-ND license. This is an open access a1. IntroductionIt is believed that long-term parenteral support (PS) and the associ-
ated provision of parenteral lipids are major causes of intestinal failure
(IF) associated liver disease (IFALD) [1,2]. However, recent studies indi-
cate that the progressive liver injury may also be inflicted independent
of PS due to the altered homeostatic feedback in the so-called gut-liver
axis as a consequence of the disrupted enterohepatic circulation follow-
ing intestinal resection, leading to biliary hypersecretion, bile acid
dysmetabolism, and microbial dysbiosis [3,4].
Mechanisms underlying liver damage and the development of IFALD
are poorly understood, and current diagnostic tools and non-invasiverticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
Research in context
Evidence before this study
In patients with SBS, extensive intestinal resections, the provision
of PS and its composition as well as an altered homeostatic feed-
back in the so-called gut-liver axis may induce liver damage
which includes a spectrum of chronic hepatic diseases, with
IFALD being the most aggressive phenotype, which can lead to
liver failure.
To identify clinical trials with the aim to investigate the effect of
exogenous GLP-2 administration on the compromised hepatic
function in patients with SBS, we searched PubMed and
MEDLINE for articles published between Jan 1, 1990 and March
31, 2019 with the search terms “short bowel syndrome”, “gluca-
gon-like peptide-2”, “glucagon-like peptide-2 analogues”, “hepatic
function”, “transient elastography”, “indocyanine green elimina-
tion”, “soluble CD163”, “soluble mannose receptor”, “lipopolysac-
charide binding protein”, “conventional liver tests”, and “adults”.
The search retrieved no clinical trials investigating the impact of
a GLP-2 analogue treatment on markers of liver status in patients
with SBS. Therefore, the current study represents a first-in-class
trial in this patient population.
Glepaglutide is a novel long-acting GLP-2 analogue with an effec-
tive plasma half-life of approx. 50 h giving this analogue the poten-
tial for less than once daily dosing. In a recently published article,
we reported findings from a randomised, double-blind, dose-
finding, single-centre, proof-of-concept, phase 2 trial, where
glepaglutide in the active doses of 1 mg and 10 mg, given subcu-
taneously once daily, significantly reduced faecal output in SBS
patients with intestinal insufficiency or failure [19]. In addition,
glepaglutide was associated with increased intestinal absorption,
improved hydration level and renal function, and was observed
to be intestinotrophic and prolong gastrointestinal transit time.
Added value of this study
Our findings in the present article are based on secondary and ex-
ploratory endpoints from the phase 2 trial and provide the first clin-
ical evidence for potential therapeutic benefit of glepaglutide on
the compromised liver function in patients with SBS. Moreover,
our findings provide a deeper insight into the complex pathophys-
iology of SBS. We have demonstrated that three weeks of treat-
ment with glepaglutide, primarily at the highest dose level of
10 mg, might improve the compromised liver excretory function,
but at the same time increase liver stiffness and activate resident
hepatic macrophages in patients with SBS. Increased splanchnic
blood flow, which is a known effect of exogenous GLP-2 adminis-
tration, may to some extend explain the findings on the excretory
liver function and liver stiffness, but not the activation of resident
hepatic macrophages.
Implications of all the available evidence
Our results in the present article suggest that glepaglutide may
play a role in the restoration of the disturbed homeostatic feedback
in the gut-liver axis and thereby SBS associated liver damage.
Thus, glepaglutidemay have therapeutic potential in the treatment
of IFALD for which no currently approved medical treatment op-
tions exists. Ongoing large multicentre, multinational, controlled
pivotal phase 3 trial (EudraCT No: 2017–004394-14) is currently
recruiting to form the basis for regulatory approval of glepaglutide
for treatment of patients with SBS in the U.S. and EU.
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suboptimal. Although liver biopsy remains the gold standard for
assessing liver inflammation and for staging liver fibrosis, its invasive
character and potential post-procedure complications limit its use as a
preferred surveillance tool. Unfortunately, clinical features and current
biochemical markers and score systems also tend to fail to properly de-
tect the degree and progression of liver damage [5],making it difficult to
initiate preventive measures and early therapeutic approaches.
In line with these unmet needs, non-invasive, easy-to-perform,
reproducible, and ultimately reliable diagnostic tools are needed.
Recently, transient elastography (TE) has been shown to correlate
with histological cholestasis and fibrosis demonstrated in one adult
and one paediatric IF population, respectively [6,7]. TE is an ultrasono-
graphic imaging modality that measures shear wave velocity which re-
flects liver stiffness. However, increase in the portal blood flow as seen
in relation to meal ingestion has been shown to increase the liver stiff-
ness [8,9]. At the same time, this technique can detect and quantify
steatosis by measuring the ultrasound attenuation.
Indocyanine green (ICG) elimination [10] is another technique
known for decades as a measure of liver function. ICG is a water-
soluble, tricarbocyanine dye which binds completely to albumin and
beta-lipoprotein after intravenous injection. ICG is taken up from the
plasma almost exclusively by the liver parenchymal cells and is excreted
unchanged by the canicular membrane into the bile [10]. Thus, de-
creased levels of elimination rate reflect impaired parenchymal liver
function, and bile excretion. The ICG elimination kinetics implies that
the substance clearance is influenced by splanchnic perfusion [10,11].
Lipid content in PS and recurrent sepsismay lead to activation of res-
ident liver macrophages (Kupffer cells) [1]. Since the activation of the
Kupffer cells plays an important role in the progressive fibrotic process,
circulating macrophage-specific markers are proposed as non-invasive
biomarkers for the diagnosis and monitoring of liver fibrosis [1,12]. In
this regard, soluble CD163 (sCD163) and soluble mannose receptor
(sMR) have received special attention. Both sCD163 and sMR are
endocytic macrophage surface receptors which are shed by activated
resident liver macrophages in response to inflammation and can be
measured in serum [12]. sCD163 in serum is predominantly present as
anectodomain cleaved form that is generated bymetalloprotease action
(tumor necrosis factor alpha-converting enzyme (TACE/ADAM17) upon
inflammatory macrophage activation. The protein may originate from
any population of activated macrophages; however, the biomarker is
especially sensitive to liver inflammation, due to the Kupffer Cells com-
prising the majority of the total macrophage pool of the body [12,34].
At present, there is no evidence-based treatment option for IFALD.
However, the introduction of glucagon-like peptide-2 (GLP-2) in the
treatment of short bowel syndrome (SBS) seems to impart a new possi-
bility for the restoration of the impaired liver function in this patient
population [3,13]. For instance, in preclinical IF settings, GLP-2 has
been shown to increase splanchnic blood flow [14,15] and improve cho-
lestasis and liver injury [3]. Native GLP-2 was also associated with in-
creased intestinal blood flow in a single clinical SBS trial [16]. On the
other hand, cholecystitis, new-onset cholelithiasis, and one episode of
cholestasis have been reported in patients with SBS in relation to treat-
ment with the marketed GLP-2 analogue teduglutide [17,18].
We have previously presented that three weeks of treatment with
daily subcutaneous injections of 1 mg and 10 mg glepaglutide resulted
in significant reductions in faecal output and improvement in intestinal
wet weight and macronutrient absorption in patients with SBS [19]. As
exploratory outcomes in this phase 2 trial, we aimed to assess changes
in marker of liver status following treatment with glepaglutide. Based
on our previous experience, we expected that treatment with
glepaglutide would decrease markers of bacterial translocation leading
to decreased levels of sCD163 and sMR and improve excretory liver
function as measured by ICG elimination. Moreover, we hypothesized
that glepaglutide would decrease liver stiffness and reduce biochemical
markers of liver injury and cholestasis.
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2.1. Study design and participants
The trial protocol was approved by Danish Medicines Agency and
the Regional Committee on Health Research Ethics and trial procedures
were conducted in accordancewith the ethical standards of theHelsinki
Declaration and the principles of Good Clinical Practice. Written in-
formed consent was signed by the patients before entrance to the trial
and before any trial-related activity was carried out. Patients could
withdraw consent at any time during the trial.
Patients with SBS associated intestinal insufficiency (II) and IF were
included from the Department of Gastroenterology and Hepatology at
Rigshospitalet, Copenhagen, Denmark, after approval from the Danish
Medicines Agency and the Regional Committee on Health Research
Ethics (Project-ID: H − 15,015,411) and based on a malabsorption
with faecal wet weight output of greater than or equal to 1500 g/day.
Carriers of Hepatitis B surface antigen (HBsAg) or Hepatitis C antibodies
and patients with a history of significant alcohol or drug abuse within
one year prior to screening were not included. Patients were also ex-
cluded, if they tested positive for HIV antibodies or had a history of can-
cer, unless it could be documented that the patient had been in a
disease-free state for at least five years (except colon cancer: patients
with a history of colon cancer were generally excluded). Details
on other main inclusion/exclusion criteria have been published
previously [19].
Patients were treated with glepaglutide in a randomised, double-
blind, dose-finding, single-centre, proof-of-concept, phase 2 trial
(ClinicalTrials.gov: NCT02690025). In a two-period cross-over design,
patients received two of three different doses (0·1 mg, 1 mg, and
10 mg) of glepaglutide as daily subcutaneous injections for a total of
three weeks. The two treatment periods were separated by a wash-
out period of four to eight weeks. The primary endpoint of the trial
was defined as the absolute change from baseline in faecal wet weight
output assessed by metabolic balance studies performed before and
after each treatment period [19]. As an exploratory endpoint, the trial
also aimed to evaluate changes from baseline in liver tests related to
treatment with glepaglutide. To minimize the effect of time as a con-
founding factor, all assessments were performed in the morning after
an oral overnight fast during hospitalisations for the metabolic balance
studies prior to and at the end of each treatment period.
2.2. Randomisation and masking
Full randomization andmasking procedures have been covered pre-
viously [19]. In summary, the effect of glepaglutide was assessed in a
two-period, three-treatment (0.1mg, 1.0mg, 10mg) cross-over design.
Six sequences (A, B, C, D, E, F) were used, corresponding to all ordered
pairs of the three treatments: A ~10 mg/1 mg, B~10 mg/0.1 mg,
C~1 mg/10 mg, D~1 mg/0.1 mg, E~0.1 mg/10 mg and F~0.1 mg/1 mg.
A sequence label thus uniquely determined the treatments allocated
for periods 1 and 2. Five blocks of length 6 were prepared; each block
representing a random ordering of A:B:C:D:E:F.
The patients were enrolled by the trial investigator, who assigned
them their patient numbers. The randomization process linked the
assigned patient numbers to the first available randomization number,
each corresponding to a sequence label. Investigators, patients and
other care providers remained masked throughout the trial.
2.3. Procedures
2.3.1. Transient elastography
Bedside transient elastography (TE) with controlled attenuation pa-
rameter (CAP) wasmeasured after an oral overnight fast by FibroScan®
502 Touch (Echosens, Paris, France) using the FibroScan M probe. The
patient was placed in a semi-recumbent position with the right arm inmaximal abduction [20]. The tip of the probe transducer was placed be-
tween the ribs perpendicularly against the skin overlying the liver. At
least ten measurements were performed after normal expiration,
targeting a success rate of ≥60% and IQR/median of ≤30% in case theme-
dian exceeded 7·1 kPa [21]. For TE the results were expressed in kPa
and for CAP the results were expressed in decibels per meter (dB/m).
2.3.2. Indocyanine green clearance examination
ICG kinetics, as measured by plasma disappearance rate (PDR, %/
min) and retention after 15 min (R15, %), were assessed after a bolus
of 0·25 mg/kg ICG (ICG-Pulsion®, Pulsion Medical Systems SE,
Feldkirchen, Germany) was injected intravenously and flushedwith sa-
line. The validated bedside pulse spectroscopy device LiMON (Pulsion,
Maquet Holding B.V. & Co., Rastatt, Germany) was applied with a
near-infraredfinger clip sensor placed on the indexfinger (LiMONMod-
ule and Sensor by LiMON PULSION) [22–24]. During the treatmentmet-
abolic balance studies, ICG-PDR and ICG-R15 were measured after
injection with glepaglutide. The principles behind the method have
been described previously [10].
2.3.3. Blood samples
Blood samples were collected for sCD163, a validated marker of
macrophage activation, sMR, and lipopolysaccharide binding protein
(LBP), a marker of gut integrity. For sCD163, sMR, and LBP, plasma
was stored at−80 °C for later analysis. Serum sCD163 and sMR were
analysed by in-house sandwich enzyme-linked immunosorbent assays
(ELISAs) [25,26]. LBP was measured using a commercially available
ELISA kit (Duoset, R&D Systems, Minneapolis, MN, USA).
Blood samples were also collected for conventional liver tests,
consisting of alkaline phosphatase (ALP), total bilirubin, international
normalised ratio (INR), albumin, and liver transaminases (ASAT and
ALAT).
2.3.4. Outcomes
As reported previously, the primary outcome of the trial was the ab-
solute change from baseline to the end of the three-week treatment pe-
riods of wet weight of faecal output measured separately over each of
the two treatment periods [19]. Main secondary and exploratory end-
points that are in the scope of the present paper included changes in:
1) stiffness of liver (TE) and CAP assessed by FibroScan, 2) ICG elimina-
tion, 3) sCD163 and sMR, 4) LBP, and 5) conventional liver tests. Amore
detailed list of additional secondary and exploratory endpoints has been
provided previously [19].
All the endpoints were assessed as changes from baselines of the in-
dividual dose groups and were evaluated during hospitalisations for
metabolic balance studies as previously described [19]. The assessments
were done prior to and at the end of each treatment period. All mea-
surements started after an oral overnight fast.
2.3.5. Statistical analysis
Since the effect of glepaglutide had not been assessed in a pilot study
prior to this phase 2 trial, no formal sample size calculation was
performed.
Baseline characteristics are reported as eithermedian (min; max) or
mean ± standard deviation (SD). An analysis of covariance (ANCOVA)
was used to assess changes from baseline within each dose group
using Statistical Analysis Software (version 9·4; SAS Institute, Cary,
NC) as detailed elsewhere [19]. Patient ID was included in the model
as a random effect to deal with within-subject correlation. The individ-
ual, period-specific baseline values of the endpoint as well as the base-
line food intake, and the period (1 or 2) as a factor were also added to
the model. Two-sided tests were performed using a 5% significance
level, and results were presented as adjustedmeans, 95% confidence in-
tervals (CI) and P-values. Since this was a dose-finding phase 2 trial,
comparison between the different dose groups were included in the
Table 1
Individual baseline demographics.
ID Sex/Age Diagnosis Anatomy SBS PS TE CAP PDR R15 sCD163 sMR LBP ALP ASAT ALAT INR Albumin Platelets Bilirubin
(years) SB
(cm)
CiC
(%)
(mL) 2–7
(kPa)
b248
(dB/m)
18–25
(%/min)
0–10
(%)
0·89–3·95
(mg/L)
0·10–0·43
(mg/L)
5–20
(μg/mL)
35–105
(U/L)
15–35
(U/L)
10–45
(U/L)
b1·2 36–45
(g/L)
145–390
(X10 [9]/L)
Total
5–25
(μmol/L)
Conjugated
0–4
(μmol/L)
Unconjugated
F: b17 μmol/L
M: b22 μmol/L
01 M/68 UC 200 0 IF 2000 8·4 ↑ 349↑ 17·7↓ 7·0 0·78↓ 0·32 1·7↓ 95 28 19 1·0 30↓ 197 7 3 5
02 M/57 UC 250 0 II 0 7·9↑ 241 22·7 3·3 2·12 0·26 2·5↓ 75 22 17 1·1 33↓ 215 9 3 6
03 F/52 CD 300 0 II 0 13·6↑ 294↑ 17·7↓ 7·0 3·08 0·36 1·9↓ 83 21 19 0·9 33↓ 249 5 2 NV
04 F/65 CD 70 0 IF 2153 5·5 180 26·6↑ 1·8 2·15 0·27 1·4↓ 61 27 9 1·0 36 187 4↓ 2 NV
05 F/61 CD 150 0 II 0 5·1 154 19·1 5·7 2·57 0·20 2·0↓ 119↑ 48↑ 21 1·3 29↓ 187 12 4 8
06 M/76 MVD 30 0 IF 5750 12·1↑ 323↑ ND ND 2·70 0·60↑ 4·6↓ 164↑ 37↑ 31 2·1↑ 30↓ 167 8 4 4
07 M/56 CD UK 0 II 0 5·0 278↑ 20·8 4·4 3·08 0·12 12·8 95 24 24 1·0 33↓ 223 3↓ 2 NV
08 F/57 MVD 80 0 IF 3500 5·5 328↑ 17·0↓ 7·8 2·27 0·28 2·1↓ 167↑ 42↑ 69↑ 1·2 36 374 18 8↑ 10
09 F/63 MVD 50 0 IF 2250 5·3 167 10·7↓ 20·1↑ 6·23↑ 0·28 1·7↓ 255↑ 32 21 1·1 34↓ 95↓ 12 6↑ 7
10 F/73 CD 30 0 IF 3130 NV NV 8·7↓ 27·1↑ 8·14↑ 0·64↑ 2·9↓ 203↑ 43↑ 29 2·4↑ 30↓ 194 13 6↑ 7
11 F/58 MVD 85 50 IF 1750 2·6 298↑ 18·5 6·2 2·32 0·26 4·1↓ 81 26 33 1·2 32↓ 297 11 5↑ 6
12 F/64 CD 150 0 IF 1000 4·6 178 15·9↓ 9·2 1·65 0·16 1·7↓ 70 28 19 1·1 34↓ 169 10 3 7
13 M/59 CD 140 0 II 0 6·0 273↑ 27·8↑ 1·5 2·76 0·32 5·1 65 17 15 1·2 31↓ 342 5 2 3
14 M/56 CD 70 0 IF 2560 NV NV ND ND 3·07 0·41 9·9 113↑ 27 12 1·0 30↓ 181 13 6↑ 7
15 M/72 CD UK 70 IF 2000 4·7 313↑ 28·4↑ 1·4 1·92 0·33 12·0 86 55↑ 82↑ 1·0 29↓ 326 9 4 5
16 M/71 MVD 40 0 IF 2750 6·1 304↑ 17·6↓ 7·1 3·28 0·32 4·6↓ 96 23 24 1·1 29↓ 140↓ 8 3 5
17 M/43 SC 70 0 IF 2865 8·8↑ 322↑ 15·8↓ 9·3 3·26 0·26 12·2 61 33 30 1·0 35↓ 249 11 5↑ 6
18 F/55 MVD 50 0 IF 3000 4·8 202 25·2↑ 2·3 4·14↑ 0·33 2·4↓ 813↑ 23 37 1·7↑ 34↓ 238 7 3 4
ALAT = Alanine Transaminase; ALP = Alkaline Phosphatase; ASAT = Aspartate Transaminase; CAP = Controlled Attenuation Parameter; CD = Crohn's Disease; CiC = Colon in continuity; F = Female; ICG = Indocyanine Green; IF = Intestinal
Failure; II = Intestinal Insufficiency; INR = International Normalised Ratio; LBP = Lipopolysaccharide Binding Protein; M =Male; MVD =Mesenteric Vascular Disease; ND = Not done; NV = Not valid; PDR = Plasma Disappearance Rate; PS
=Parenteral Support; R15=Retention Rate after 15min; SB=Small Bowel; SBS=Short Bowel Syndrome; SC=Surgical Complications; sCD163=Soluble CD163; sMR=SolubleMannose Receptor; TE=Transient Elastography; UC=Ulcerative
Colitis; UK = Unknown.
447
R.M
.N
aim
ietal./EBioM
edicine
46
(2019)
444–451
448 R.M. Naimi et al. / EBioMedicine 46 (2019) 444–451ANCOVA model. Type 3 analysis in the model was used to assess dose
dependency.
The Spearman rank correlations were performed to assess any asso-
ciation between variables. The trial was monitored by a contract re-
search organisation (Larix A/S, Denmark) and is registered at
ClinicalTrials.gov with registration number NCT02690025.Fig. 1.Mean changes from baseline in transient elastography.3. Results
Of the 18 patients randomised and treatedwith glepaglutide (13 pa-
tientswith SBS-IF and fivewith SBS-II) between February 2016 andMay
2017, 16 patients completed the trial, thereby comprising the full anal-
ysis set group. The last patient's follow-up visit wasMay 4, 2017. Demo-
graphics and baseline characteristics are shown in Table 1.
No patients had ascites and successful baseline TEwas performed in
16 out of 18 (89%) patients.Mean TE (±SD)was 6·6±2·9 kPa (median
5·5 kPa (min: 2·6; max: 13·6)) and mean CAP was 262 ± 66 dB/m
(median 286 dB/m (154; 349)) at baseline. Of the 16 patients, five pa-
tients had TE N7 kPa (cut-offs for liver fibrosis stage ≥ F1 [20]); two
out of five patients (40%) in SBS-II group and three out of 11 patients
(27%) in the SBS-IF group. CAP value was above 248 dB/m (cut-offs for
steatosis N S0 [27]) in ten out of 16 patients; three out of five (60%) pa-
tients with SBS-II and seven out of 11 (64%) patients with SBS-IF. Fol-
lowing treatment with glepaglutide, TE tended to increase in the 1 mg
and 10 mg dose groups, but not in the 0·1 mg dose group. However,
no dose-dependency was observed (P = .103), and the changes did
not reach statistical significance (Table 2 and Fig. 1). CAP did not change
in any of the dose groups.
Mean ICG-PDR at baselinewas 19·4± 5·7%/min andmean ICG-R15
was 7·6 ± 6·9%. At baseline, ICG-PDR was below the lower limits of
normal (LLN) in eight patients; among them seven patients had SBS-
IF. ICG-R15 was elevated in two patients with SBS-IF at baseline. A
dose response relationship was observed between 1 mg and 10 mg
doses of glepaglutide and changes in ICG-PDR and ICG-R15 (Fig. 2).
However, only changes in the 10 mg dose group reached statistical sig-
nificance; ICG-PDR increased by 4%/min (P= 0·0006) and ICG-R15 de-
creased by 2% (P= 0·024) (Table 2) corresponding to a relative changeTable 2
Transient elastography, controlled attenuation parameter, indocyanine green, sCD163,
sMR and LBP.
Changes from
baseline
(Adjusted means
[95% CI])
0·1 mg
(N= 10)
1 mg
(N= 11)
10 mg
(N = 11)
TE (kPa) -1·0 [−2·5, 0·45]
P = 0·162*
0·7 [−0·7,
2·1]
P = 0·289**
1.1 [−0·3, 2·5]
P = 0·122*
CAP (dB/m) 12 [−19, 42]
P = 0·432*
17 [−10, 45]
P = 0·198**
−11 [−39, 17]
P = 0·434*
ICG-PDR (%/min) −1·7 [−3·9, 0·5]
P = 0·129
1·6 [−0·8,
4·0]
P = 0·183*
4·0 [1·9, 6·1]
P = 0·0006
ICG-R15 (%) 1·4 [−0·5, 3·2]
P = 0·145
−1·3 [−3·3,
0·7]
P = 0·184*
−2·0 [−3·8,
−0·3]
P = 0·024
sCD163 (mg/L) 0·14 [−0·32, 0·61] P =
0·513
0·05 [−0·40,
0·49]
P = 0·824
0·44 [0·00,
0·88]
P = 0·0498
sMR (mg/L) 0·03 [−0·01, 0·07]
P = 0·115
0·00 [−0·04,
0·04]
P = 0·985
0·03 [−0·00,
0·07]
P = 0·068
LBP (μg/mL) −0·21 [−3·24, 2·82]
P = 0·881
1·33 [−1·57,
4·23]
P = 0·330
0·77 [−2·07,
3·61]
P = 0·561
*N= 9; **N = 10; CAP = Controlled Attenuation Parameter; ICG = Indocyanine Green;
LBP= Lipopolysaccharide Binding Protein; PDR=PlasmaDisappearance Rate; R15=Re-
tention Rate after 15 min; sCD163 = Soluble CD163; sMR= Soluble Mannose Receptor;
TE = Transient Elastography; N = number of patients in full analysis set;of 19% and− 37% respectively. No changeswere observed in the 0·1mg
dose group.
Mean sCD163 at baseline was 3·1 ± 1·7 mg/mL, mean sMRwas 0·3
± 0·1 mg/mL and mean LBP was 4·8 ± 4·0 μg/mL. Elevated levels
(higher than the reference range 97·5 percentile for healthy individuals
[26,28]) of sCD163 (0·89–3·95 mg/L) and sMR (0·10–0·43 mg/L) were
observed in three and two SBS-IF patients, respectively. LBP was below
LLN in 13 out of 18 (72%) patients. In the 10 mg dose group, sCD163 in-
creased by 0·44 mg/mL (P = 0·0498). In general, sCD163 increased in
eight of 11 (73%) patients within the range of 0·01–1·6 mg/mL. How-
ever, the post-treatment values for these patients were still within the
normal range [28] (Fig. 3). A decrease in serum levels of sCD163was ob-
served in the 10 mg dose group in two patients with baseline values
above upper limits of normal (ULN). A non-significant increase of
0·03 mg/mL (P = 0·068) was observed for sMR in the 10 mg dose
group. However, the magnitude of the increase was comparable with
changes following0·1mg(0·03mg/mL;P=0·115). sMRdidnot change
following treatment with 1 mg glepaglutide (0·00; P = 0·985). No
changes were observed in LBP following treatment with glepaglutide.
Biochemical cholestasis as defined by elevated plasma levels of ALP
N1·5 fold theULN [29]was observed at baseline infive of the 18patients
(28%), all having SBS-IF. Conjugated bilirubin was elevated in six of the
18 patients (33%), all having SBS-IF. Total and unconjugated bilirubin
values were within the normal range in all patients. INR was above
1·2 in three (17%) patients with SBS-IF; two patients with the shortest
small bowel length of 30 cm without colon and one with the need for
warfarin due to protein S deficiency. ALAT levels were elevated, but
still b2 xUNL in two patientswith SBS-IF. Plasma albuminwas generally
low in all patients (Table 1). In the 1 mg dose group, treatment with
glepaglutide resulted in a decrease of 33 U/L (P = 0·032) in plasma
ALP from baseline value of 189 ± 216 U/L, and a reduction of 2·1 g/L
(P = 0·023) in plasma albumin from baseline value of 32·0 ± 1·8 g/L
(Table 3). Minor decreases were observed in plasma total bilirubin
(−2 μmol/L, P = 0·016) and unconjugated bilirubin (−1·3 μmol/L, P
= 0·035) in the 10 mg dose group. Liver transaminases (ASAT and
ALAT), conjugated bilirubin and INR did not change in any dose groups.
4. Discussion
We have previously published that three weeks of treatment with
glepaglutide in a randomised, dose-finding phase 2 trial was associated
with improvement of the intestinal function in patientswith SBS [19]. In
this paper, we report that short term treatment with glepaglutide may
Fig. 2.Mean changes from baseline in ICG-PDR and ICG-R15.
449R.M. Naimi et al. / EBioMedicine 46 (2019) 444–451improve liver excretory function, increase liver stiffness, and activate
resident liver macrophages in patients with SBS as exploratory out-
comes from the phase 2 trial. These findings were not in full support
of our a priori expectations and are ambiguous in the sense that some
of themmay be interpreted as beneficial, others as reflecting potentially
harmful effects.
Our findings suggest that alterations in markers of liver function are
evident in a stable SBS population with or without need for PS at base-
line. However, except for TE and CAP, a clear overrepresentation of pa-
tients with SBS-IF had biochemical cholestasis, impaired hepatic
clearance of ICG aswell as elevated levels of sCD163 and sMR.Moreover,
small bowel length and the PS volume requirements correlated with
baseline values of ALP, ALAT, conjugated and total bilirubin, sMR, and
sCD163 (the latter only with small bowel length), but not ICG-PDR/
R15 or LBP (appendix page 2–3).Fig. 3. Individual serum levels of sCD163 and sMRTE in an adult IF population have only been assessed in one previous
trial [6], where patients with different pathophysiological aetiology of IF
were included with liver function ranging from no significant hepatic al-
terations to overt clinical signs of severe liver disease [30]. Thismight ex-
plainwhy themedian TE (10·0 (4; 24) kPa) in that studywashigher than
what we have found in the present trial, where only stable patients with
SBS-II and SBS-IF without significant abnormal liver biochemistry were
included. Our data do not confirm previous findings concerning the neg-
ative correlation between TE and the severity of SBS as indicated by small
bowel length and PS volume [6,7]. However, our findings suggest that
the severity of SBS at baselinemay be a predictor of an increase in TE fol-
lowing treatment with glepaglutide (appendix page 2–3). Since PS vol-
ume was kept stable during the trial, we could not assess whether a
change in PS volume following the treatmentwould also induce a change
in TE.before and after treatment for each patient.
Table 3
Liver tests.
Changes from baseline
(Adjusted means [95%
CI])
0·1 mg
(N= 10)
1 mg
(N= 11)
10 mg
(N = 11)
ALAT (U/L) 0·0 [−14·0,
14·0]
P = 0·999
−4·1 [−16·8,
8·7]
P = 0·497
3·4 [−9·5,16·3]
P = 0·568
ALP (U/L) 9 [−23, 40]
P = 0·556
−33 [−63,−4]
P = 0·032
−16 [−46,14]
P = 0·255
Total Bilirubin (μmol/L) −0·2
[−1·8,1·5]
P = 0·838
−0·3
[−1·8,1·3]
P = 0·718
−1·9 [−3·4,
−0·5]
P = 0·016
Conjugated Bilirubin
(μmol/L)
0·4 [−0·4, 1·2]
P = 0·287
−0·2 [−1·0,
0·5]
P = 0·515
−0·4 [−1·1,
0·4]
P = 0·358
Unconjugated Bilirubin
(μmol/L)
0·2 [−1·0, 1·4]
P = 0·710
0·2 [−1·0, 1·3]
P = 0·732
−1·3 [−2·4,
0·1]
P = 0·035
INR −0·02 [−0·09,
0·06]
P = 0·682
0·07[−0·01,
0·14]
P = 0·080
−0·00
[−0·08,0·07]
P = 0·925
Plasma Albumin (g/L) −1·2 [−3·1,
0·6]
P = 0·173
−2·1 [−3·9,
−0·4]
P = 0·023
−1·2 [−3·0,
0·6]
P = 0·165
ALAT=Alanine Transaminase; ALP=Alkaline Phosphatase; INR= International Normal-
ised Ratio; N = number of patients in full analysis set.
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may indicate increased liver stiffness. This is often ascribed to fibrosis,
which however is unlikely to develop with our short intervention.
Liver stiffness may also result from a number of transient changes
such as cellular infiltration as part of inflammation. The increase in
sCD163 could support this background and if so would be a cause of at-
tention. However, liver stiffness also increases with splanchnic blood
flow [8,31], not measured here but known in other studies to increase
by exogenous GLP-2 administration even in a fasting condition [16].
Thus the increase in TEmay partly be ascribed to hemodynamic changes
which might be taken to be beneficial.
The increase in ICG elimination along with the reduction in ALP and
total bilirubinmay imply that glepaglutide benefits excretory liver func-
tion in patients with SBS. These positive effects might bemediated indi-
rectly through the improved intestinal absorption, allowing a greater
portal circulation of fluids and nutrients. Thiswas supported by the pos-
itive correlations between changes in ICG-PDR/R15 and changes in wet
weight absorption, as well as negative correlations between baseline
values of ALP/total bilirubin and wet weight absorption (appendix
page 2–3). However, changes in splanchnic perfusion may influence
the results since ICG clearance is dependent on hepatic blood flow
[10]. Other possible explanatory mechanisms may include activation
of the FXR-FGF19-C4 (FXR= Farnesoid X Receptor, FGF19= Fibroblast
Growth Factor 19, C4 = 7α-Hydroxy-4-Cholesten-3-One) gut-liver
axis, alterations in bile acid composition and output as well as improve-
ments in the enterohepatic circulation.
Recent experimental and clinical evidence available may suggest
that the main trigger in IFALD is resident liver macrophage activation
caused by synergistic effects of parenteral plant sterols present in intra-
venous lipid preparations and bacterial translocation [32,33]. The
resulting portal inflammation then leads to suppression of transporters
for bile acids, sterols, phospholipids and bilirubin. Somewhat contrary
to this hypothesis, alterations in markers of liver function were ob-
served at baseline independent of LBP, which was not elevated in any
patients included in this trial and did not seem to correlate with either
PS volume or small bowel length (appendix page 2–3). Moreover,
glepaglutide improved ICG and markers of cholestasis, but also in-
creased sCD163 without significant effects on LBP that in any case is a
relatively insensitive marker of LPS load.The increase in sCD163 in the 10 mg dose group indicate some de-
gree of inflammatory activation of resident liver macrophages. sCD163
did not seem to correlatewith either changes in ICG-PDR or the increase
in wet weight absorption (appendix page 2–3) suggesting that the ef-
fects of glepaglutide on ICG clearance and sCD163 were independent
of each other. The increase in sCD163, contrary to ICG clearance and
liver stiffness, cannot be ascribed to hemodynamic or other confound-
ing effects.
Given that our findings are based on results from the exploratory
endpoints of the phase 2 trial with a limited number of patients and
with no sample size calculation, the results and the level of significance
presented in this paper should be interpreted with care. Type 2 errors
are possible due to the small sample size. However, type 1 errors should
also be considered when interpreting these results given the number of
tests we have performed in this small sample, including the correlation
analysis. Moreover, as far as we know, the methods used in this study,
apart from conventional liver tests, have not been used previously to as-
sess liver function in a stable chronic SBS populationwith II or IF. The as-
sessmentswere performedwith at least threeweeks gap; i.e. we neither
have data on the acute changes after glepaglutide administration, nor
the consequences of long-term, potentially chronic treatment, which
would be of interest. The clinical relevance of our findings should be ad-
dressed in larger studies withmore robust designs that include patients
with overt IFALD to validate the methods and assess their suitability as
diagnostic or surveillance tools thatwould eventually help in proper de-
tection of the degree and progression of hepatic damage in patients
with SBS.
In conclusion, short-term treatment with glepaglutide induced in-
creases in TE, ICG elimination, sCD163 as well as a reduction in
plasma ALP, and total bilirubin. CAP and gut integrity as assessed
by LBP were not measurably affected. Although there was no signif-
icant difference between the 1 mg and 10 mg dose groups regarding
any of the abovementioned assessments, changes were primarily
seen in the 10 mg dose group. No treatment effect was observed
for the 0·1 mg dose, which was congruent with our previous find-
ings since glepaglutide at this dose level did not impact intestinal
function [19]. The increase in elimination of ICG may imply an im-
proved liver excretory function supported by the reductions in ALP
and total bilirubin. The increase may also be suggestive of an increase
in splanchnic and thereby hepatic blood flow as supported by the
positive correlations between changes in ICG elimination and
changes in wet weight absorption. The increases in sCD163 and TE
may imply liver macrophage activation and an increased hepatic
stiffness, respectively, both reflecting cellular inflammation in the
liver, although the stiffness could also increase by higher splanchnic
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